Pharmaceutical co-crystal

被引：844

作者：

Vishweshwar, P ^{[1
]}

McMahon, JA ^{[1
]}

Bis, JA ^{[1
]}

Zaworotko, MJ ^{[1
]}

机构：

[1] Univ S Florida, Dept Chem, Tampa, FL 33620 USA

来源：

JOURNAL OF PHARMACEUTICAL SCIENCES | 2006年 / 95卷 / 03期

关键词：

crystal engineering; hydrogen bond; pharmaceutical co-crystal; polymorphism; supramolecular synthesis;

D O I：

10.1002/jps.20578

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Crystal engineering has evolved in such a manner that it is now synonymous with the paradigm of supramolecular synthesis, that is, it invokes self-assembly of existing molecules to generate a wide range of new solid forms without the need to break or form covalent bonds. This review addresses how crystal engineering has been applied to active pharmaceutical ingredients, API's, with emphasis upon how pharmaceutical co-crystals, a long known but little explored alternative to the four traditionally known forms of API, can be generated in a rational fashion. Case studies on Carbamazepine (CBZ) and Piracetam are presented which illustrate the relative ease with which pharmaceutical co-crystals can be prepared and their diversity in terms of composition and physical properties. (c) 2006 Wiley-Liss, Inc. and the American Pharmacists Association.

引用

页码：499 / 516

页数：18

共 150 条

[1] Building co-crystals with molecular sense and supramolecular sensibility [J].